CagriSema Combination Drug to Be Tested for Kidney Protection in Diabetes

Chronic Kidney Disease (CKD) and Type 2 Diabetes often co-exist, leading to severe health complications, particularly in individuals living with overweight or obesity. While existing treatments like semaglutide improve glycemic control and weight, their specific efficacy in directly reducing kidney damage in this high-risk population, especially when combined with other agents, remains to be fully elucidated. This study aims to determine if the novel combination of cagrilintide and semaglutide (CagriSema) can more effectively reduce kidney damage compared to individual components or placebo.

As this is a completed design abstract for a Phase 2 study, the actual efficacy and safety results are not yet available, but the study's primary objective is clearly defined. The trial has successfully enrolled 626 participants, indicating a robust sample size for a Phase 2 investigation into this novel combination therapy. The study is designed to assess whether CagriSema (co-administered cagrilintide 2.4 mg and semaglutide 2.4 mg) demonstrates superior efficacy in reducing kidney damage and improved safety profiles compared to semaglutide 2.4 mg, cagrilintide 2.4 mg, and placebo. The study aims to quantitatively compare changes in kidney function markers and safety endpoints across the four treatment arms, with data collection ongoing until November 2025. This design will provide crucial insights into the comparative benefits of the combination versus monotherapies.